Sugi Predict

Sugi Predict / Compounds / SCHEMBL3007008

SCHEMBL3007008

SCHEMBL3007008

O=C[C@H](OCc1ccccc1)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC1A3 P43003 2/20 0.42
▸ SLC1A2 P43004 2/20 0.42
▸ SLC1A1 P43005 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ RCE1 Q9Y256 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ HCAR2 Q8TDS4 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16059792 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL10351575 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL9095023 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL27671067 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL1560449 0.95 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL5271501 0.95 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL27671081 0.95 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL4601140 0.95 SLC1A3 (0.43) SLC1A3SLC1A2SLC1A1KMT2AMEN1
Deoxyglucose SCHEMBL27671070 0.92 SLC1A3 (0.37) SLC1A3SLC1A2SLC1A1KMT2AMEN1
Butyl Alcohol SCHEMBL27866800 0.90 CTSK (0.36) SLC1A3SLC1A2SLC1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117886958-A Nine-sugar and preparation method and application thereof 艾立斯特(合肥)生物科技有限公司 2024-04-16 — — CN claimed
WO-2012107207-A1 SWEETENER AND/OR A SWEETNESS ENHANCER, SWEETENER COMPOSITIONS, METHODS OF MAKING AND USING SAME, AND CONSUMABLES CONTAINING SAME NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) 2012-08-16 — — WO claimed
EP-1758452-B1 METABOLICALLY STABLE ANALGESICS AND PAIN MEDICATIONS HUMAN BIOMOLECULAR RES INST (US) 2017-01-25 — — EP disclosed
US-8481501-B2 Synthesis of metabolically stable analgesics, pain medications and other agents HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2013-07-09 — — US disclosed
WO-2012107207-A1 SWEETENER AND/OR A SWEETNESS ENHANCER, SWEETENER COMPOSITIONS, METHODS OF MAKING AND USING SAME, AND CONSUMABLES CONTAINING SAME NUTRINOVA NUTRITION SPECIALTIES & FOOD INGREDIENTS GMBH (DE) 2012-08-16 — — WO disclosed
US-20100190728-A1 Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2010-07-29 — — US disclosed
EP-1758452-A4 SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS HUMAN BIOMOLECULAR RES INST (US) 2009-08-05 — — EP disclosed
EP-1758452-A1 SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS Human Biomolecular Research Institute (US) 2007-03-07 — — EP disclosed
WO-2005117589-A1 SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) 2005-12-15 — — WO disclosed
US-6562514-B1 Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries PINNACLE VRB LIMITED (AU) 2003-05-13 — — US disclosed
EP-1261614-A2 METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2002-12-04 — — EP disclosed
US-6468688-B2 CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE PINNACLE VRB LIMITED (AU) 2002-10-22 — — US disclosed
US-20010028977-A1 Charging, discharging efficiency; vanadium electrolyte JD HOLDING INC. (KY) 2001-10-11 — — US disclosed
WO-2001068659-A2 METHOD FOR THE PRODUCTION OF PERBENZYLATED 1-O GLYCOSIDES SCHERING AKTIENGESELLSCHAFT (DE) 2001-09-20 — — WO disclosed
US-6143443-A ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE PINNACLE ARB LIMITED (AU) 2000-11-07 — — US disclosed
WO-2000064917-A2 SYNTHETIC INDOLOCARBAZOLE REGIOISOMERS AND USES THEREOF ADVANCED LIFE SCIENCES INC. (US) 2000-11-02 — — WO disclosed
EP-0829104-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1998-03-18 — — EP disclosed
WO-1996035239-A1 HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS UNISEARCH LIMITED (AU) 1996-11-07 — — WO disclosed
EP-0354322-A2 Antidiabetic alpha-substituted phosphonates AMERICAN CYANAMID COMPANY (US) 1990-02-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190728-A1 Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents OPRK1, OPRL1, OPRM1 SLC1A3 558/4885SLC1A2 147/4885SLC1A1 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.